WEREWOLF THERAPEUTICS, INC. Restricted Cash and Cash Equivalents, Noncurrent
WEREWOLF THERAPEUTICS, INC. (HOWL) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2026-09-22
- 2026-06-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2026-03-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2025-12-31: Restricted Cash and Cash Equivalents, Noncurrent $901.00K.
- 2025-09-30: Restricted Cash and Cash Equivalents, Noncurrent $898.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2026-06-30 | $0.00 S-4 · filed 2026-09-22 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $901.00K S-4 · filed 2026-09-22 |
| 2025-09-30 | $898.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $895.00K S-4 · filed 2026-09-22 |
| 2025-03-31 | $891.00K 10-Q · filed 2026-05-07 |
| 2024-12-31 | $1.22M S-4 · filed 2026-09-22 |
| 2024-09-30 | $1.22M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $1.21M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $21.03M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $21.02M 10-K · filed 2025-03-11 |
| 2023-09-30 | $21.02M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $21.02M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $21.01M 10-Q · filed 2024-05-03 |
| 2022-12-31 | $1.21M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |